Clinical Trials Browser

Hyperthermia, Breast Neoplasms

NCT06926868 2026-04-30

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

549 enrolled

Breast

Breast Neoplasms, Recurrence

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT01779206 2025-04-08

ADAPT

Phase 2/3 Completed

4,936 enrolled

Breast

Breast Neoplasms

NCT05747794 2024-12-17

AIPAC-003

Phase 2/3 Active not recruiting

849 enrolled

Breast

Breast Neoplasms

NCT05189535 2024-01-23

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

Phase 2/3 Completed

66 enrolled

Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT03150576 2022-11-14

PARTNER

Phase 2/3 Recruiting

780 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01057069 2022-10-12

neo-TN

Phase 2/3 Active not recruiting

310 enrolled

Breast

Breast Neoplasms

NCT03580395 2021-07-09

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Phase 2/3 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Phase 2/3 Withdrawn

Breast

Breast Neoplasms

NCT01572727 2017-03-09

BELLE-4

Phase 2/3 Completed

416 enrolled 11 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Clinical Trials

NeoHTerMa

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

OPTIMAL

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

ADAPT

AIPAC-003

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

PARTNER

neo-TN

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

BELLE-4